Search bioRxiv⌕ Search

Biology subjects

Jung-Hynes, B.

Publications and source records attributed to Jung-Hynes, B..

3 recordsLinked to original sources

Droplet-array culture enables single-cell isolation of bacteria directly from blood

Bacteremia and sepsis require rapid diagnosis and treatment, but these are often hampered by slow or inconclusive blood culture results. Here we describe an alternative to traditional blood culture, leveraging common laboratory equipment and a droplet array to isolate and expand bacteria in a single step. The method neutralizes inhibitory whole-blood components through lysis, concentrates sample bacteria, and uses a droplet array to enable single-bacteria isolation and subsequent in-droplet expansion. Seven species of bacteria (four gram negative, three gram positive) were spiked into 1 mL of whole blood at a concentration of approximately 100 colony-forming units (CFU) and subsequently processed. The mean time to colorimetric detection via WST-8 dye was 11.5 h (range 9-13 h), compared with [≥] 28 h typically required for conventional blood culture and subculture. Colony counts per droplet followed a Poisson distribution for both gram-negative ({lambda} = 0.288) and gram-positive ({lambda} = 0.320) organisms, and means of 86.2% and 88.4% of occupied droplets, respectively, contained a single CFU. This method eliminates the need for additional subculture after positive blood culture. By partitioning the sample, the workflow limits competitive exclusion and preserves the composition of polymicrobial samples, while yielding viable colonies substantially faster than conventional methods. Blood processing at low CFU counts (3-5 CFU/mL) with both S. aureus and E. coli consistently recovered viable bacteria (1-3 CFU/mL).

microbiology↗

Comparative study of GenePOC GBS LB Assay and GeneXpert GBS LB Assay for the detection of Group B Streptococcus in prenatal screening samples.

Group B Streptococcal (GBS) infections in the United States are a leading cause of meningitis and sepsis in newborns. The CDC, therefore recommends GBS screening for all pregnant women at 35-37 weeks of gestation and administration of intrapartum prophylaxis (in those that tested positive) as an effective means of controlling disease transmission. Several FDA approved molecular diagnostic tests are available for rapid and accurate detection of GBS in antepartum women. In this study, we report a clinical comparison of the Xpert GBS LB assay and a novel FDA-cleared test, GenePOC GBS LB assay. A total of 250 vaginal-rectal swabs from women undergoing prenatal screening were submitted to the University of Wisconsins clinical microbiology laboratory for GBS testing. We found 96.8% of samples were concordant between the two tests, while 3.2% were discordant with higher sensitivity observed for the GenePOC GBS LB assay, and higher specificity for the GeneXpert GBS LB assay.

microbiology↗

Performing Reflexive Toxin A/B Enzyme Immunoassay in a Two-Step Algorithm for the Diagnosis of Clostridium difficile Infection Has Limited Clinical Utility

The differentiation of Clostridium difficile infection (CDI) from colonization is challenged by the suboptimal clinical specificity of nucleic acid amplification tests (NAAT). In this study, we examined the utility of testing for toxin via enzyme immunoassay (EIA) in specimens already tested by NAAT for the diagnosis of CDI in an attempt to differentiate colonization from infection. We tested 59 stool samples for the presence of C. difficile toxin B gene by NAAT followed by EIAs for glutamate dehydrogenase (GDH EIA) and toxins A and B (Toxin EIA). Two infectious disease physicians independently reviewed the patients electronic medical records retrospectively to categorize each patient as CDI-Likely, CDI-Unlikely, or CDI-Indeterminate. Clinical sensitivities and specificities were calculated using 3 definitions of \"true\" CDI status, being: (1) concordance between both reviewers, (2) concordance, and CDI-Indeterminate/discordant cases classified as CDI-Likely, and (3) concordance, and CDI-Indeterminate/discordant cases classified as CDI-Unlikely. Based on these definitions, clinical sensitivity and specificity for NAAT was 100% and 49-94%, GDH EIA was 83-85% and 43-89%, and Toxin EIA was 39-42% and 83-100%, respectively. 85% (22 of 26) of patients who were NAAT-positive but Toxin EIA-negative symptomatically benefited from treatment for CDI. The addition of EIA to NAAT for CDI diagnosis had limited utility for differentiating colonization from CDI and could have led to under treatment of patients with CDI.

microbiology↗